Gleevec

(Imatinib)

ApprovedProtein / enzyme

Imatinib is used to treat certain types of cancer, particularly chronic myeloid leukemia (a blood cancer) and gastrointestinal stromal tumors. It works by blocking proteins that help cancer cells grow and divide.[2] Gleevec is currently approved and in use across 104 indications[4].[1]

Gleevec is one of 1821 small molecule programs targeting Glioma. It is currently in Approved.

104

Indications

427

Total Trials

Active Trials

1,820

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Polycythemia VeraActive, not recruiting

FibrosarcomaApproved

Cirrhosis of LiverApproved

ChordomaActive, not recruiting

Non-Hodgkins LymphomaApproved

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

Clear Cell Renal CarcinomaApproved

Colonic NeoplasmApproved

NeurofibromatosisActive, not recruiting

GliomaPhase 1/Phase 2

Active, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

FibrosarcomaApproved

Approved

Cirrhosis of LiverApproved

Approved

ChordomaPhase 2

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

Adult Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Clear Cell Renal CarcinomaApproved

Approved

Colonic NeoplasmApproved

Approved

NeurofibromatosisPhase 2

Active, not recruiting

Showing 10 of 103 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

8 2

Halaven

Eisai

Preclinical

38 3

Tecentriq

Roche

Preclinical

36 4

Trodelvy

Gilead

Preclinical

37 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Gastrointestinal Stromal Tumor

NCT01991379

Phase 2Active, not recruiting

Combination Therapy

NCT07022743

Post-ApprovalRecruiting

Children

NCT03844360

Q1 2027

Phase 2Recruiting

Gastrointestinal Stromal Tumour

NCT05009927

Q2 2027

Phase 2Recruiting

Melanoma

NCT04598009

Q3 2027

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT03589326

Clinical

Trials by Indication[1]

Myeloid Leukemia22 trials

Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase

Completed·UUniversity of Bologna·Phase 2·NCT00514969

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

Unknown status·—·Phase 1·NCT03228303·100 enrolled

TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study

Completed·UUniversity of Pisa··NCT01860456·412 enrolled

Show 19 more trials

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Completed· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 2·NCT04126681·144 enrolled

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

Terminated· Novartis logo

Novartis·Phase 3·NCT00124748·476 enrolled

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Completed·HHospital Universitario Dr. Jose E. Gonzalez·Phase 3·NCT01819389·10 enrolled

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Completed· Pfizer logo

Pfizer··NCT05286528·1,484 enrolled

Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan

Completed·HHikma Pharmaceuticals LLC··NCT02977312·91 enrolled

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Active, not recruiting·SSWOG Cancer Research Network·Phase 2·NCT03654768·81 enrolled

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Completed·IIl-Yang Pharm. Co., Ltd.·Phase 3·NCT01511289·242 enrolled

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto··NCT01475110·19 enrolled

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 4·NCT05367765·2,400 enrolled

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Completed· Novartis logo

Novartis·Phase 2·NCT03578367·104 enrolled

Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

Completed·HHikma Pharmaceuticals LLC··NCT03454503·173 enrolled

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Terminated·AAriad Pharmaceuticals·Phase 3·NCT01650805·307 enrolled

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT01188889

A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia

Completed·UUppsala University·Phase 2·NCT01227356·112 enrolled

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

Completed· Novartis logo

Novartis·Phase 2·NCT00171158·260 enrolled

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 1/2·NCT00028847·60 enrolled

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01751425·8 enrolled

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Completed·PPoitiers University Hospital·Phase 4·NCT00845221·44 enrolled

Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

Unknown status·LLynn McMahon·Phase 2·NCT01227135·66 enrolled

Acute Lymphoblastic Leukemia18 trials

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00081133

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

Show 15 more trials

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00763763·55 enrolled

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002514·1,929 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT01025505·40 enrolled

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Unknown status·PPETHEMA Foundation·Phase 4·NCT01491763·70 enrolled

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Active, not recruiting· Takeda logo

Takeda·Phase 3·NCT03589326·245 enrolled

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Completed·MMassachusetts General Hospital·Phase 2·NCT00973752·30 enrolled

Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00458848·470 enrolled

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT01005914·11 enrolled

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01383447·2 enrolled

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01312818·2 enrolled

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03007147·475 enrolled

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·N/A·NCT00049569·126 enrolled

Gastrointestinal Stromal Tumor16 trials

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01991379·75 enrolled

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

Completed· Novartis logo

Novartis·Phase 2·NCT01172548·132 enrolled

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Completed· Novartis logo

Novartis·Phase 2·NCT00237185·148 enrolled

Show 13 more trials

Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

Unknown status·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT04138381·30 enrolled

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04933669·122 enrolled

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT03862768·92 enrolled

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Recruiting·CCentre Leon Berard·Phase 2·NCT05152472·110 enrolled

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00573404·6 enrolled

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02257541·16 enrolled

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00009906·748 enrolled

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00324987·12 enrolled

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

Recruiting·—·Phase 2·NCT05385549·35 enrolled

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 2·NCT00764595·5 enrolled

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Completed· Novartis logo

Novartis·Phase 4·NCT00171977·64 enrolled

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

Completed· Novartis logo

Novartis·Phase 4·NCT00510354·28 enrolled

Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

Completed·TTechnical University of Munich·Phase 2·NCT00112632·40 enrolled

Chronic Myelogenous Leukemia15 trials

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Completed· Novartis logo

Novartis·Phase 3·NCT00471497·846 enrolled

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054431·80 enrolled

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00015834·46 enrolled

Show 12 more trials

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Completed· Novartis logo

Novartis·Phase 2·NCT00006475

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Completed· Novartis logo

Novartis·Phase 1/2·NCT00093639

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Completed·HHeidelberg University·Phase 3·NCT00055874·1,551 enrolled

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00415909·3 enrolled

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia

Unknown status·MMeng Li·Phase 2·NCT02687425·20 enrolled

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00110058·40 enrolled

STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Completed· Novartis logo

Novartis·Phase 2·NCT00006053

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Completed· Novartis logo

Novartis·Phase 3·NCT00006343

STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

Completed· Novartis logo

Novartis·Phase 2·NCT00006052

Autologous Transplantation for Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01003054·24 enrolled

Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Completed·—·Phase 1·NCT00301093·3 enrolled

Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00045422

Treatment6 trials

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Terminated·AAB Science·Phase 3·NCT00812240·335 enrolled

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Active, not recruiting·HHeikki Joensuu·Phase 3·NCT02413736·255 enrolled

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting·PPETHEMA Foundation··NCT06175702·150 enrolled

Show 3 more trials

Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT

Completed·—·Phase 3·NCT01151852·81 enrolled

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

Completed· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 3·NCT02204644·400 enrolled

Entacapone Combination With Imatinib for Treatment of GIST

Completed·XXiangya Hospital of Central South University·Phase 1·NCT04006769·5 enrolled

91 more indications

Non-Small Cell Lung Cancer4 trials

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

Completed·NNew Mexico Cancer Research Alliance·Phase 2·NCT01011075·34 enrolled

Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·UUniversity of Washington·Phase 2·NCT00408460·34 enrolled

Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT00323362·17 enrolled

Show 1 more trial

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01083589·22 enrolled

Fibrosis3 trials

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

Completed·MMassachusetts General Hospital·Phase 2·NCT00677092·12 enrolled

Effect of Imatinib in Advance Liver Fibrosis Patients

Unknown status·RResearch Institute for Gastroenterology and Liver Diseases (RIGLD)·Phase 1/2·NCT05224128·20 enrolled

Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec

Completed·UUniversity of Aarhus·Phase 3·NCT00981942·10 enrolled

Acute Myeloid Leukemia3 trials

A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT01126814·35 enrolled

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

Completed·—·Phase 2·NCT00509093·32 enrolled

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Withdrawn·UUniversity of Cincinnati·Phase 2·NCT00594555·20 enrolled

COVID-193 trials

A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.

Withdrawn·EExvastat Ltd.·Phase 2·NCT04953052

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Unknown status·SSunnybrook Health Sciences Centre·Phase 3·NCT04330690·2,900 enrolled

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT04488081·1,500 enrolled

Melanoma3 trials

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00074308·40 enrolled

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

Completed·—·Phase 2·NCT00424515·24 enrolled

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT04598009·25 enrolled

Breast Cancer3 trials

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193180·37 enrolled

Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)

Recruiting·VVastra Gotaland Region·N/A·NCT05722795·40 enrolled

S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00087152·27 enrolled

Meningioma2 trials

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Completed·—·Phase 2·NCT00354913·21 enrolled

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

Unknown status·IIstituto Scientifico H. San Raffaele·Phase 2·NCT00904735·76 enrolled

Pneumonia2 trials

The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

Unknown status·—·Phase 3·NCT04422678·30 enrolled

Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

Unknown status·HHospital Universitario de Fuenlabrada·Phase 2·NCT04346147·168 enrolled

Pulmonary Arterial Hypertension2 trials

Positioning Imatinib for Pulmonary Arterial Hypertension

Unknown status·IImperial College London·Phase 2·NCT04416750·17 enrolled

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

Completed· Novartis logo

Novartis·Phase 2/3·NCT00477269·59 enrolled

GIST2 trials

A Study of Nilotinib Versus Imatinib in GIST Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00785785·644 enrolled

Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

Unknown status·SShanghai Zhongshan Hospital··NCT03381053·3,000 enrolled

Asthma2 trials

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT04129931·395 enrolled

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Completed·—·Phase 2·NCT01097694·176 enrolled

Colorectal Cancer2 trials

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00041340·37 enrolled

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Terminated· Novartis logo

Novartis·Phase 1·NCT01271166·10 enrolled

Myelofibrosis2 trials

Imatinib Mesylate in Treating Patients With Myelofibrosis

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00245128·10 enrolled

Imatinib Mesylate in Treating Patients With Myelofibrosis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00039416·18 enrolled

Glioma2 trials

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Completed·—·Phase 2·NCT00615927·64 enrolled

Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00021229·85 enrolled

Ovarian Cancer2 trials

Gleevec Study for Patients With Ovarian Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00510653·73 enrolled

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

Completed·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 2·NCT00928642·8 enrolled

Leukemia2 trials

High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)

Completed·NNantes University Hospital·Phase 2·NCT00707408·15 enrolled

Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00244829

Scleroderma2 trials

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Unknown status·AAzienda Ospedaliera Universitaria Policlinico·Phase 2·NCT00573326·30 enrolled

Efficacy and Safety of Imatinib in Scleroderma

Completed·UUniversity Hospital, Bordeaux·Phase 2·NCT00479934·28 enrolled

Tyrosine Kinase Inhibitors2 trials

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT01188278·173 enrolled

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Completed·MMedical College of Wisconsin·Phase 2·NCT02269267·173 enrolled

Small Cell Lung Cancer2 trials

Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193349·60 enrolled

Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·UUniversity Health Network, Toronto·Phase 1·NCT00052494·9 enrolled

Metastatic Melanoma2 trials

Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma

Completed·PPeking University·Phase 2·NCT00881049·1 enrolled

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Withdrawn·JJoanne Jeter·Phase 1/2·NCT02812693

Dermatofibrosarcoma Protuberans2 trials

Imatinib in Dermatofibrosarcoma Protuberans (DFSP)

Completed·DDermatologic Cooperative Oncology Group·Phase 1/2·NCT00122473·30 enrolled

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00084630·40 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

Completed·UUniversity Hospital, Lille·Phase 2·NCT02891395·65 enrolled

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

Unknown status·TThe University of Hong Kong·Phase 2·NCT03241199·15 enrolled

Interaction1 trial

Drug-drug Interaction Study With Metformin and Imatinib

Completed·UUniversity of California, San Francisco·Phase 1·NCT01404715·11 enrolled

Refractory1 trial

Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

Terminated·SSeoul National University Hospital·Phase 2·NCT01898377·9 enrolled

Chondrosarcoma1 trial

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

Completed·IItalian Sarcoma Group·Phase 2·NCT00928525·35 enrolled

Malignancies1 trial

Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial

Enrolling by invitation·PPoitiers University Hospital··NCT06646978·787 enrolled

Targeted Therapy1 trial

Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

Terminated·UUMC Utrecht·Phase 2·NCT02685046·5 enrolled

Malignant Peripheral Nerve Sheath Tumor1 trial

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Terminated· Novartis logo

Novartis·Phase 2/3·NCT00427583·11 enrolled

Systemic Mastocytosis1 trial

Imatinib in KIT-negative Systemic Mastocytosis

Completed·HHospital Virgen de la Salud·Phase 4·NCT01297777·10 enrolled

Tyrosine Kinase Inhibitor1 trial

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

Completed·—·Phase 2·NCT02712112·51 enrolled

Malignant Glioma1 trial

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT00010049·105 enrolled

Kidney Cancer1 trial

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00331409·23 enrolled

Soft Tissue Sarcoma1 trial

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1/2·NCT00006357·91 enrolled

Stem Cell Transplantation1 trial

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

Completed·PPoitiers University Hospital·Phase 2·NCT00219726·30 enrolled

Salivary Gland Cancer1 trial

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00045669·16 enrolled

Pilot Study1 trial

LAM Pilot Study With Imatinib Mesylate

Completed·MMedical University of South Carolina·Phase 1/2·NCT03131999·18 enrolled

Chronic Graft Versus Host Disease1 trial

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

Completed·DDavid Miklos·Phase 1·NCT00760981·15 enrolled

Concentration1 trial

Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes

Completed·FFirst Affiliated Hospital, Sun Yat-Sen University··NCT06628739·168 enrolled

Adjuvant1 trial

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00415857·5 enrolled

Clinical Trial1 trial

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03891901·24 enrolled

Thyroid Carcinoma1 trial

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00115739·11 enrolled

Children1 trial

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Recruiting·WWei Zhao·Phase 4·NCT03844360·1,500 enrolled

Malaria1 trial

Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

Unknown status·NNurex S.r.l.·Phase 2·NCT03697668·50 enrolled

Chronic Myelomonocytic Leukemia1 trial

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00079313·7 enrolled

Stem Cell Transplant1 trial

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Not yet recruiting·TThe University of Hong Kong·Phase 2·NCT07493408·45 enrolled

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Adenoid Cystic Carcinoma1 trial

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00180921·30 enrolled

Acute Lymphoblastic Leukaemia1 trial

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting·MMats Heyman·Phase 3·NCT04307576·6,430 enrolled

Combination Therapy1 trial

Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy

Active, not recruiting·OObafemi Awolowo University·Phase 2·NCT07022743·75 enrolled

Sickle Cell Disease1 trial

Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease

Withdrawn·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT01568645

Relapsed or Refractory1 trial

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Terminated·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 1/2·NCT02462538·3 enrolled

Spinal Cord Injury1 trial

Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study

Unknown status·PProfessor Mikael Svensson, MD PhD·Phase 2·NCT02363361·10 enrolled

Fibromatosis1 trial

Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Withdrawn·MMedPacto, Inc.·Phase 2·NCT06219733

Adult Acute Lymphoblastic Leukemia1 trial

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00376467·105 enrolled

Bone Marrow Transplantation1 trial

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Completed· Incyte logo

Incyte·Phase 3·NCT03112603·330 enrolled

Hematologic Malignancies1 trial

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02352558·15 enrolled

Ocular Melanoma1 trial

Imatinib in Adult Patients With Metastatic Ocular Melanoma

Terminated·CCentre Oscar Lambret·Phase 2·NCT00421317·13 enrolled

Chemotherapy1 trial

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT05071482·39 enrolled

Efficacy1 trial

To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.

Unknown status·PPeking University··NCT03424876·60 enrolled

Glioblastoma Multiforme1 trial

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Terminated· Novartis logo

Novartis·Phase 2·NCT00290771·231 enrolled

Gastrointestinal Stromal Tumour1 trial

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Recruiting·CCentre Leon Berard·Phase 2·NCT05009927·50 enrolled

Liver Resection1 trial

Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM

Completed·FFirst Affiliated Hospital, Sun Yat-Sen University··NCT06038552·238 enrolled

Thyroid Cancer1 trial

A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

Terminated·AAHS Cancer Control Alberta·Phase 1·NCT03469011·14 enrolled

Stroke1 trial

Imatinib in Acute Ischaemic Stroke

Unknown status·NNiaz Ahmed·Phase 3·NCT03639922·1,260 enrolled

Rare Tumor1 trial

PLATFORM Study of Precision Medicine for Rare Tumors

Recruiting·—·Phase 2·NCT04423185·770 enrolled

Diffuse Scleroderma1 trial

Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

Terminated·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT01545427·10 enrolled

Rare Diseases1 trial

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Completed· Novartis logo

Novartis·Phase 2·NCT00154388·185 enrolled

Pancreatic Cancer1 trial

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

Completed·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00161213·44 enrolled

Brain Tumor1 trial

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00049127·64 enrolled

Gastric Cancer1 trial

A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00068380·17 enrolled

Plasmodium falciparum malaria1 trial

Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

Completed·HHuLow·Phase 1·NCT02614404·15 enrolled

MPA1 trial

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Completed·IInhibikase Therapeutics·Phase 1·NCT05623774·64 enrolled

Head and Neck Squamous Cell Cancer1 trial

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00485485·7 enrolled

Hematologic Cancer1 trial

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT00064285·22 enrolled

Tics1 trial

Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers

Completed·JJan Beumer·Phase 1·NCT00732784·11 enrolled

Kaposi's sarcoma1 trial

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00090987·30 enrolled

Prostate Cancer1 trial

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00500110·39 enrolled

Preoperative1 trial

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST

Not yet recruiting·FFujian Medical University Union Hospital·Phase 3·NCT05970900·23 enrolled

Pleural Mesothelioma1 trial

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

Completed·IIstituto Clinico Humanitas·Phase 2·NCT02303899·22 enrolled

Metastatic Colorectal Cancer1 trial

New Individualized Therapy Trial for Metastatic Colorectal Cancer

Completed·IInova Health Care Services·Phase 1/2·NCT00867334·10 enrolled

CML1 trial

Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients

Completed·UUniversity of Milano Bicocca·Phase 4·NCT01578213·112 enrolled

Primary Peritoneal Cancer1 trial

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00036751·40 enrolled

Patients With Advanced Solid Tumors1 trial

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

Completed·HHerbert Hurwitz·Phase 1·NCT00253565·25 enrolled

Plexiform Neurofibroma1 trial

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Terminated·SSt. Justine's Hospital·Phase 2·NCT02177825·5 enrolled

Advanced Cancer1 trial

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00025415·60 enrolled

Neurofibromatosis1 trial

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Withdrawn·IIndiana University·Phase 2·NCT03688568

Idiopathic Pulmonary Fibrosis1 trial

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

Completed·—·Phase 2/3·NCT00131274·120 enrolled

Prospective1 trial

STI571 ProspectIve RandomIzed Trial: SPIRIT

Completed·PPoitiers University Hospital·Phase 3·NCT00219739·789 enrolled

Polycythemia Vera1 trial

Effects of Imatinib Mesylate in Polycythemia Vera

Completed·NNiguarda Hospital·Phase 2·NCT00430066·9 enrolled

Systemic Sclerosis1 trial

Imatinib in Systemic Sclerosis

Completed·SStanford University·Phase 1/2·NCT00506831·9 enrolled

Unspecified4 trials

Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib

Completed· Novartis logo

Novartis·Phase 1·NCT00422825·16 enrolled

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

Completed· Novartis logo

Novartis·Phase 1·NCT00420043·32 enrolled

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

Completed·UUniversity of Pittsburgh·Phase 1·NCT00446004·15 enrolled

Show 1 more trial

Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate

Completed·CCentre Oscar Lambret·Phase 1·NCT01046487·26 enrolled

Regulatory

FDA Approval Timeline[5]

May 10, 2001

GLEEVEC

NDA NDA021335

Apr 18, 2003

GLEEVEC

NDA NDA021588

Nov 22, 2024

IMKELDI

NDA NDA219097

Sources

References

[1]
ClinicalTrials.gov — 427 trial records for Imatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Gleevec drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Imatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Imatinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219097). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Gleevec. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Bcr/abl Fusion Protein Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Beta Inhibitor; Tyrosine-Protein Kinase ABL Inhibitor[3]
Modality: Protein / enzyme[3]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[6]

Patent Cliff

Apr 27, 2040

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11957681Apr 27, 2040